COG2 and coronary artery disorder: According to the 2018 ACC/AHA [25], the 2019 ESC/EAS [26], and the adult treatment panel III (ATP III) cholesterol guidelines [27], LDL-C was considered the major cause of CAD and treated as the primary target for therapy, while other lipids were used as the secondary or supplementary therapeutic targets.